<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769209</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-25596</org_study_id>
    <secondary_id>NCI-2012-03094</secondary_id>
    <secondary_id>HEMALL0008</secondary_id>
    <secondary_id>IRB-25596</secondary_id>
    <nct_id>NCT01769209</nct_id>
  </id_info>
  <brief_title>Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the value of bortezomib in combination with specified chemotherapies for
      the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
      Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
      cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      Determine the response rate of bortezomib in combination with a chemotherapy backbone of
      doxorubicin (doxorubicin hydrochloride), vincristine (vincristine sulfate), PEG-asparaginase
      (pegaspargase), and dexamethasone in patients with relapsed/refractory acute lymphoblastic
      leukemia.

      SECONDARY OBJECTIVES:

        -  Estimate the rate of complete response (CR) and CR with incomplete platelet recovery
           (CRp) on Day 29 after re-induction.

        -  Determine progression-free survival (PFS) at 2 years after re-induction.

        -  Determine failure-free survival (FFS) at 1 year after re-induction.

        -  Overall survival (OS) at 1 year after re-induction.

        -  Assess safety and tolerability of the study drug.

        -  Determine whether bortezomib induces reactive oxygen species (ROS) in circulating acute
           lymphoblastic leukemia (ALL) blast cells.

      OUTLINE:

      Patients receive bortezomib subcutaneously (SC) on Days 1, 4, 8, and 11; doxorubicin
      hydrochloride intravenously (IV) on day 1; pegaspargase IV or intramuscularly (IM) on Days 5
      and 22; vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) daily on
      Days 1 to 14; cytarabine intrathecally (IT) on Day 1 and methotrexate intrathecally (IT) on
      Day 15. Patients with central nervous system disease receive intrathecal treatment per
      investigator's discretion.

      Participants are followed up every 3 months for up to 2 years after completion of study
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Day 29</time_frame>
    <description>Response Rate (RR) was determined as the sum of complete response (CR) and partial response (PR). Due to overlap, &quot;complete response rate without platelet recovery&quot; (CRp) is not included in Response Rate (RR). The outcome is reported as the total number without dispersion.
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.
PR = Meets all criteria for CR except bone marrow contains 5 to 25% leukemia cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>Day 29</time_frame>
    <description>Complete response (CR) was determined the number of participants who achieved CR by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. CR is defined as:
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
Not CR = All statuses and conditions if less than or not as defined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Without Platelet Recovery (CRp)</measure>
    <time_frame>Day 29</time_frame>
    <description>Complete response without platelet recovery (CR) was determined as the number of participants who achieved CRp by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. The outcome reflects only those subjects that meet all complete response (CR) criteria except platelet count; participants that meet all criteria including platelet count are not included in this outcome. CR and CRp are defined below.
CR =.No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival (PFS) was assessed as survival without progression at 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free Survival (FFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Failure-free survival (FFS) was assessed as survival without progression or the addition of another systemic therapy, at or within 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression. Progression is defined below.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) was assessed as participants remaining alive 2 years after induction therapy. The outcome is reported as the number of participants (without dispersion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Adverse Events (Grade 3, 4, 5)</measure>
    <time_frame>45 days</time_frame>
    <description>Toxicity was assessed as related grade 3, 4, or 5 adverse events (AEs) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. The outcome is reported as the total numbers of events (without dispersion) by CTCAE Body System, and whether the event was a hematologic toxicity or non-hematologic toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of Reactive Oxygen Species (ROS)</measure>
    <time_frame>2 years</time_frame>
    <description>Circulating acute lymphoblastic leukemia (ALL) blast cells were to be evaluated for the presence of reactive oxygen species (ROS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>B-cell Adult Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>T-cell Adult Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride (HCl)</intervention_name>
    <description>Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Adria</other_name>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Rubex</other_name>
    <other_name>VXLD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Asparaginase</intervention_name>
    <description>Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Pegaspargase</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>L-asparaginase with polyethylene glycol</other_name>
    <other_name>Pegasparaginase</other_name>
    <other_name>PEG-L-asparaginase</other_name>
    <other_name>PEG-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
    <description>Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Vincasar PFS</other_name>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Administered intrathecally (IT) at 100 mg, on Day 1</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Cytosine arabinoside</other_name>
    <other_name>ARA-C</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered intrathecally (IT) at 15 mg, on Day 15.</description>
    <arm_group_label>Bortezomib + Chemotherapy</arm_group_label>
    <other_name>Amethopterin</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Voluntary written informed consent

          -  Female subjects who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  form through 30 days after the last dose of bortezomib, or agree to completely
                  abstain from heterosexual intercourse

          -  Male subjects, even if surgically sterilized (ie, status post vasectomy) who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through a minimum of 30 days after the last dose of study
                  drug, OR

               -  Agree to completely abstain from heterosexual intercourse

          -  â¢ Relapsed or refractory B or T cell acute lymphoblastic leukemia that has progressed
             following at least one prior therapy. Ph+ patients are eligible. Relapsed ALL is
             defined in patients as the reappearance of leukemia cells in the peripheral blood or
             bone marrow or appearance of extramedullary disease after a complete remission.
             Refractory ALL is defined in patients as failure to achieve a complete remission after
             induction therapy. Complete remission is defined by &lt;5% leukemia cells in the bone
             marrow with recovery of peripheral blood counts. Relapsed disease can be documented by
             bone marrow biopsy (&gt;5% cells in the bone marrow) or by flow cytometry in the
             peripheral blood or biopsy of extramedullary disease.

          -  Has received at least 1 line of prior systemic therapy that may NOT have included
             bortezomib (Velcade); patients who have undergone autologous/allogeneic stem cell
             transplantation are eligible

          -  Transplant-eligible patients are eligible

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  No poorly-controlled intercurrent illness including, but not limited to, ongoing or
             active infection, poorly controlled diabetes, symptomatic congestive heart failure, or
             psychiatric illness that in the opinion of the investigator would limit compliance
             with study requirements

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 x upper
             limit of normal (ULN)

          -  Total bilirubin â¤ 1.5 x (ULN unless elevation is deemed due to leukemia infiltration)

          -  Adequate renal function defined as creatinine clearance of â¥ 30 mL/minute by the
             Cockcroft-Gault method

        EXCLUSION CRITERIA

          -  &gt; 1.5 x ULN total bilirubin

          -  â¥ Grade 2 peripheral neuropathy

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any
             electrocardiogram (ECG) abnormality at screening must be documented by the
             investigator as not medically relevant

          -  Hypersensitivity to bortezomib, boron, or mannitol

          -  Pregnant or lactating

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Participation in clinical trials with other investigational agents not included in
             this trial throughout the duration of this trial

          -  Radiation therapy within 3 weeks before randomization; enrollment of subjects who
             require concurrent radiotherapy (which must be localized in its field size) should be
             deferred until the radiotherapy is completed and 3 weeks have elapsed since the last
             date of therapy

          -  Prior exposure â¥ 350 mg/mÂ² of anthracycline (doxorubicin equivalent)

          -  Left ventricular ejection fraction &lt; 40%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Liedtke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>September 12, 2018</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>October 14, 2018</last_update_submitted>
  <last_update_submitted_qc>October 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michaela Liedtke</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib + Chemotherapy</title>
          <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib + Chemotherapy</title>
          <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR)</title>
        <description>Response Rate (RR) was determined as the sum of complete response (CR) and partial response (PR). Due to overlap, &quot;complete response rate without platelet recovery&quot; (CRp) is not included in Response Rate (RR). The outcome is reported as the total number without dispersion.
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.
PR = Meets all criteria for CR except bone marrow contains 5 to 25% leukemia cells.</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR)</title>
          <description>Response Rate (RR) was determined as the sum of complete response (CR) and partial response (PR). Due to overlap, &quot;complete response rate without platelet recovery&quot; (CRp) is not included in Response Rate (RR). The outcome is reported as the total number without dispersion.
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.
PR = Meets all criteria for CR except bone marrow contains 5 to 25% leukemia cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response (CR)</title>
        <description>Complete response (CR) was determined the number of participants who achieved CR by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. CR is defined as:
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
Not CR = All statuses and conditions if less than or not as defined.</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR)</title>
          <description>Complete response (CR) was determined the number of participants who achieved CR by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. CR is defined as:
CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
Not CR = All statuses and conditions if less than or not as defined.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Without Platelet Recovery (CRp)</title>
        <description>Complete response without platelet recovery (CR) was determined as the number of participants who achieved CRp by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. The outcome reflects only those subjects that meet all complete response (CR) criteria except platelet count; participants that meet all criteria including platelet count are not included in this outcome. CR and CRp are defined below.
CR =.No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Without Platelet Recovery (CRp)</title>
          <description>Complete response without platelet recovery (CR) was determined as the number of participants who achieved CRp by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. The outcome reflects only those subjects that meet all complete response (CR) criteria except platelet count; participants that meet all criteria including platelet count are not included in this outcome. CR and CRp are defined below.
CR =.No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) &gt; 1,000/microliter; platelets &gt; 100,000/microliter; &lt; 5% blasts in bone marrow.
CRp = Meets all criteria for CR except platelet count.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) was assessed as survival without progression at 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) was assessed as survival without progression at 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure-free Survival (FFS)</title>
        <description>Failure-free survival (FFS) was assessed as survival without progression or the addition of another systemic therapy, at or within 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression. Progression is defined below.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Failure-free Survival (FFS)</title>
          <description>Failure-free survival (FFS) was assessed as survival without progression or the addition of another systemic therapy, at or within 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression. Progression is defined below.
Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was assessed as participants remaining alive 2 years after induction therapy. The outcome is reported as the number of participants (without dispersion).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was assessed as participants remaining alive 2 years after induction therapy. The outcome is reported as the number of participants (without dispersion).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Adverse Events (Grade 3, 4, 5)</title>
        <description>Toxicity was assessed as related grade 3, 4, or 5 adverse events (AEs) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. The outcome is reported as the total numbers of events (without dispersion) by CTCAE Body System, and whether the event was a hematologic toxicity or non-hematologic toxicity.</description>
        <time_frame>45 days</time_frame>
        <population>Events specifically defined per protocol as &quot;Hematologic Toxicity&quot; or&quot;Non-hematologic Toxicity&quot; are included under the specific Body System and as a Hematologic or Non-hematologic Toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Related Adverse Events (Grade 3, 4, 5)</title>
          <description>Toxicity was assessed as related grade 3, 4, or 5 adverse events (AEs) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. The outcome is reported as the total numbers of events (without dispersion) by CTCAE Body System, and whether the event was a hematologic toxicity or non-hematologic toxicity.</description>
          <population>Events specifically defined per protocol as &quot;Hematologic Toxicity&quot; or&quot;Non-hematologic Toxicity&quot; are included under the specific Body System and as a Hematologic or Non-hematologic Toxicity.</population>
          <units>Treatment-related adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and Lymphatic System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and Nutrition Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction of Reactive Oxygen Species (ROS)</title>
        <description>Circulating acute lymphoblastic leukemia (ALL) blast cells were to be evaluated for the presence of reactive oxygen species (ROS).</description>
        <time_frame>2 years</time_frame>
        <population>Assay development was unsuccessful, and the assessment and analysis were not conducted for any samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib + Chemotherapy</title>
            <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction of Reactive Oxygen Species (ROS)</title>
          <description>Circulating acute lymphoblastic leukemia (ALL) blast cells were to be evaluated for the presence of reactive oxygen species (ROS).</description>
          <population>Assay development was unsuccessful, and the assessment and analysis were not conducted for any samples.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib + Chemotherapy</title>
          <description>Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
Bortezomib: Administered subcutaneously (SC) at 1.3 mg/mÂ², on Days 1, 4, 8, and 11.
Doxorubicin hydrochloride (HCl): Administered intravenously (IV) over 15 min at 60mg/mÂ², on Day 1.
PEG-Asparaginase: Administered intravenously (IV) or intramuscularly (IM) 2500 U/mÂ² (maximum 3750 U), on Days 5 and 22.
Vincristine sulfate: Administered by intravenous (IV) push at 1.5 mg/mÂ² (maximum 2 mg), on Days 1, 8, 15, and 22.
Dexamethasone: Administered orally (PO) at 10 mg/mÂ², daily on Days 1 to 14.
Cytarabine: Administered intrathecally (IT) at 100 mg, on Day 1
Methotrexate: Administered intrathecally (IT) at 15 mg, on Day 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever (febrile neutropenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation (DIC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon and caecum inflammation (typhilitis, colitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobilliary Disorders-Other, veno-occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock (sepsis)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever (febrile neutropenia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitations (tachycardia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Heart failure (congestive heart failure)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased hearing (hearing impaired)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting (nausea)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease (GERD)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colon and caecum inflammation (typhilitis, colitis)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Perianal pain ( Anal pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling (edema)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobilliary Disorders-Other, liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations-Other,thrush</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory infections</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and infestations-Other, Herpes simplex virus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Septic shock (sepsis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus (RSV)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infections and infestations-Other, Herpes simplex virus Line, sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT) high</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase (AST) elevated</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase (ALT) elevated</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bilirubin elevated</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase elevated</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyl transferase (GGT) elevated</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Amylase high</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase high</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Creatinine high</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Apetite loss (anorexia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia (Albumin low)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia (Triglycerides high)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypernatremia -Sodium high</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia -Sodium low</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia -Potassium low</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia -Potassium high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia -Magnesium low</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcemia -Calcium low</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia -Phosphorus low</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolism and Nutrition Disorders-Other Phosphorus high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycemia (Glucose high)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoglycemia -Glucose low</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg weakness (generalized muscle weakness )</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Avascular necrosis (Bone infarct)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Restless leg (akathisia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain during urination (dysuria)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Breath shortness (Dyspnea)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest pain (pleuritic pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nosebleed (Epistaxis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin ulceration -Lip lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure (hypertension)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Low blood pressure (hyportension)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michaela Liedtke, MD</name_or_title>
      <organization>Stanford University Medical Center</organization>
      <phone>650-498-6000</phone>
      <email>mliedtke@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

